In the latest trading session, Pfizer (PFE) closed at $42.06, marking a -0.92% move from the previous day. This change lagged the S&P 500's daily loss of 0.69%.Heading into today, shares of the drugmaker had lost 6.89% over the past month, outpacing the Medical sector's loss of 8.36% and lagging the S&P 500's loss of 2.58% in that time.PFE will be looking to display strength as it nears its next earnings release, which is expected to be November 2, 2021. In that report, analysts expect PFE to post earnings of $1.10 per share. This would mark year-over-year growth of 52.78%. Our most recent consensus estimate is calling for quarterly revenue of $22.41 billion, up 84.74% from the year-ago period.For the full year, our Zacks Consensus Estimates are projecting earnings of $4.08 per share and revenue of $80.86 billion, which would represent changes of +83.78% and +69.71%, respectively, from the prior year.Any recent changes to analyst estimates for PFE should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.73% higher. PFE is currently a Zacks Rank #3 (Hold).Investors should also note PFE's current valuation metrics, including its Forward P/E ratio of 10.4. Its industry sports an average Forward P/E of 13.47, so we one might conclude that PFE is trading at a discount comparatively.Also, we should mention that PFE has a PEG ratio of 1.55. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.06 at yesterday's closing price.The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 117, putting it in the top 47% of all 250+ industries.The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Tech IPOs With Massive Profit Potential In the past few years, many popular platforms and like Uber and Airbnb finally made their way to the public markets. But the biggest paydays came from lesser-known names. For example, electric carmaker X Peng shot up +299.4% in just 2 months. Think of it this way… If you had put $5,000 into XPEV at its IPO in September 2020, you could have cashed out with $19,970 in November. With record amounts of cash flooding into IPOs and a record-setting stock market, this year’s lineup could be even more lucrative.See Zacks Hottest Tech IPOs Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report To read this article on Zacks.com click here.